Abstract:Delivery of various forms of recombinant Theileria parva sporozoite antigen (p67) has been shown to elicit antibody responses in cattle capable of providing protection against East Coast fever, the clinical disease caused by T. parva. Previous formulations of full-length and shorter recombinant versions of p67 derived from bacteria, insect, and mammalian cell systems are expressed in non-native and highly unstable forms. The stable expression of full-length recombinant p67 in mammalian cells has never been des… Show more
“…However, p67C had several advantages over the full-length protein when expressed in E. coli , such as better stability and higher expression yields [13] , [15] . A very recent study has demonstrated stable expression of p67 without the transmembrane domain in mammalian cells [23] . It will be interesting to determine the efficacy of this antigen in vaccine trials.…”
HighlightsThree doses of p67C antigen generated stronger immune responses than two doses.Antibody titers and CD4+ T-cell proliferation correlated with protection against ECF.The number of doses could not be reduced from three to two without compromising the protection.
“…However, p67C had several advantages over the full-length protein when expressed in E. coli , such as better stability and higher expression yields [13] , [15] . A very recent study has demonstrated stable expression of p67 without the transmembrane domain in mammalian cells [23] . It will be interesting to determine the efficacy of this antigen in vaccine trials.…”
HighlightsThree doses of p67C antigen generated stronger immune responses than two doses.Antibody titers and CD4+ T-cell proliferation correlated with protection against ECF.The number of doses could not be reduced from three to two without compromising the protection.
“…Previous attempts to express recombinant T. parva proteins in prokaryotic or eukaryotic systems for vaccine purposes have been challenging and the process has been hindered due to protein insolubility and misfolding, among other issues (15, 16, 20). Recently, we were able to express full-length T. parva p67 antigen in mammalian cells and demonstrated that the recombinant antigen retained its immunogenic properties (21). Considering the technical and biological challenges associated with the expression of Theileria sp.…”
Section: Discussionmentioning
confidence: 99%
“…Concomitantly with the identification of novel antigens was extensive work to optimize antigen expression systems and delivery platforms for Theileria antigens. Both prokaryotic and eukaryotic systems have been tested for expression of potential T. parva vaccine antigens (15, 16, 20, 21). Codon usage, post-translational modifications, protein conformation, and solubility are a few aspects that have been considered in deciding the most suitable platform to express antigens for subunit vaccines.…”
Section: Introductionmentioning
confidence: 99%
“…Codon usage, post-translational modifications, protein conformation, and solubility are a few aspects that have been considered in deciding the most suitable platform to express antigens for subunit vaccines. Recently, we examined the antigenicity of the full-length T. parva p67 protein expressed in a mammalian system, and that work provided a basis for further studies to investigate this recombinant, mammalian expressed antigen as a subunit vaccine component to prevent T. parva (21).…”
East Coast Fever (ECF), caused by the tick-borne apicomplexan parasite
Theileria parva
, is a leading cause of morbidity and mortality in cattle of sub-Saharan Africa. The infection and treatment method (ITM) is currently the only vaccine available to control
T. parva
. Although ITM elicits levels of protection, its widespread adoption is limited by costs, laborious production process, and antibiotic co-treatment requirement, necessitating the development of a more sustainable vaccine. To this end, efforts have been concentrated in the identification of new
T. parva
vaccine antigens and in the development of suitable platforms for antigen expression. In this study, we investigated the molecular and antigenic properties of
T. parva
antigen Tp9 expressed by mammalian cells. Data indicate that Tp9 contains a signal peptide that is weakly functional in mammalian cells. Thus, Tp9 secretion from mammalian cells increased 10-fold after the native signal peptide was replaced with the human tissue plasminogen activator signal peptide (tPA). Sera from all
T. parva
-immune cattle recognized this recombinant, secreted Tp9. Additionally, PBMC from ITM-immunized cattle produced significant (
p
< 0.05) amounts of IFNγ following
ex vivo
exposure to Tp9, but this response varied between cattle of different MHC class I and class II genotypes. In addition, depletion experiments demonstrated that IFNγ to Tp9 was primarily produced by CD4
+
T cells. Molecular analysis demonstrated that Tp9 presents a signal peptide that is weakly functional in mammalian cells, suggesting that it remains within lymphocytes during infection. Tp9 secretion from mammalian cells was substantially increased when the tPA secretion signal sequence was substituted for the native secretion signal sequence. Using full-length, recombinant Tp9 secreted from mammalian cells, we demonstrated that
T. parva
-immune cattle develop both humoral and cellular immune responses to this antigen. Collectively, these results provide rationale for further evaluation of Tp9 as a component of a
T. parva
subunit vaccine.
“…Later, the NheI/SmaI cut amplicons were cloned into the shuttle vector pINT2EGFP (25) and cut with the same enzymes, generating pCMV-tPA-MMP, pCMV-tPA-MMP-5mut, and pCMV-tPA-MMP-2mut, thereby placing the tPA-MMP ORFs under the transcriptional control of the immediate early gene promoter of human cytomegalovirus (CMV), followed by the bovine growth hormone polyadenylation signal (pA). Alternatively, the NheI/SmaI cut amplicons were subcloned into the vector pEF1α-p67 (26) to put the tPA-MMP ORFs under the transcriptional control of the Human Elongation Factor 1 Alpha (EF1α) promoter followed by the bovine growth hormone pA, thus generating pEF1α-tPA-MMP, pEF1α-tPA-MMP-5mut, and pEF1α-tPA-MMP-2mut.…”
Section: Sequence Analysis and Cloning Of Mmpmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.